Poietis has developed a patented Next Generation Bioprinting (NGB) platform that utilizes Laser-Assisted Bioprinting and bio-extrusion techniques to create complex 3D tissue models with micron-level precision. This technology enables researchers and clinicians to produce viable, implantable tissues, facilitating advancements in regenerative medicine and accelerating the transition from research to clinical applications.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for creating 3D tissue models often lack the precision and versatility needed for advanced tissue engineering and regenerative medicine applications. Existing bioprinting techniques may not adequately support the creation of complex tissue structures with high cell viability and resolution, hindering progress in both research and clinical settings.
Solution
Poietis offers the Next Generation Bioprinting (NGB) platform, a high-end bioprinting solution that combines laser-assisted bioprinting and bio-extrusion techniques to enable the creation of complex 3D tissue models. The NGB platform allows for micron-level precision in depositing cell bioinks, supporting a variety of cell types and materials with different viscosities. This nozzle-free system maintains high cell viability throughout the bioprinting process. The NGB platform is available in two versions: NGB-R™ for research applications and NGB-C™ for clinical applications, facilitating the transition from research to clinical use.
Target Audience
The primary audience includes researchers in tissue engineering and regenerative medicine, as well as hospitals and clinics focused on cell therapies and translational research for clinical applications such as implantable tissues.
Features
- Laser-assisted bioprinting for high-resolution cell deposition with micron-level precision.
- Bio-extrusion capability to print a variety of bioinks with different viscosities, cell types, and materials.
- Nozzle-free system to ensure high cell viability during bioprinting.
- Multimodal robotic laser assistance.
- Integrated microscope coupled with ViewPrintTM software.
- NGB-R™ version for research applications.
- NGB-C™ version compatible with Good Manufacturing Practices (GMP) for clinical applications and production of implantable bioprinted tissue.
- Robotic platform and automation of processes for reproducible manufacturing of complex tissues.